[20] ZHOU R, LI H, YANG H, et al. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis [J]. Mult Scler Relat Disord, 2022, 58: 103446. [21] COYLE P K, K...
A spokesperson for Sandoz said: Patient safety is our first priority. We are seeking to understand the situation at Imperial healthcare NHS trust, which appears to contrast with the experience of patients at other UK hospitals. We believe its premature to draw conclusions at this point. We cont...
[25]Reich DS, ArnoldDL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oralbrain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b,randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol. 2021Sep;20(9):729-738。
4. Sormani MP, Gasperini C, Romeo M, et al.Assessing response to interferon-b in a multicenter dataset of patients with MS. Neurology 2016;87:134–140. 5. Sormani MP, Rio J, Tintorè M, et al.Scoring treatment response in patients wi...
You can lose your ability to control your bowel or bladder functions, or to engage in intercourse. Become a Patient You Deserve a Personalized Care Plan that Fits Your Life Goals and Your MS At the Boster Center for Multiple Sclerosis, it is our goal to help you live your very best life...
The first episode of optic neuritis occurred in a patient who was later diagnosed with MOGAD.#Our study demonstrated a favorable safety profile with no serious adverse events associated with COVID-19 vaccines in patients with MS, NMOSD, and MOGAD....
In people with MS, the body's own immune system attacks the tissue surrounding the nerve fibers in the brain, spinal cord, and optic nerves. This covering is made of a fatty substance called myelin. It insulates the nerves and helps them send electrical signals that control movement, speech...
the intervention's availability), the intervention's cost, and the expected variation in patient pr...
The new trial found that Kesimpta consistently beat Aubagio in sending MS into remission, regardless of patient race/ethnicity. The trial involved people with relapsing-remitting MS. As the researchers explained, this is MS in its most common stage, characterized by flare-ups of symptoms followed ...
It is not known if PLEGRIDY is safe and effective in people under 18 or over 65 years of age. Important Safety Information Who should not take PLEGRIDY? Do not take PLEGRIDY if you are allergic to interferon beta or peginterferon, or any of the other ingredients in PLEGRIDY What is the ...